Article
?
AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button.
Tier 2
?
Original research — experimental, observational, or case-control study. Direct primary evidence.
Human Health Effects
Nanoplastics
Sign in to save
Microplastics and Nanoplastics in Atheromas and Cardiovascular Events
New England Journal of Medicine2024
843 citations
?
Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count.
Score: 75
?
0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Rosalba La Grotta,
Gianluca Fulgenzi,
Celestino Sardu,
Maurizio Municinò,
Giulia Matacchione,
Olivieri Fabiola,
Carmine Lubritto,
Angelo Fenti,
Simona Galoppo,
Pasquale Iovino,
Raffaele Marfella,
Lucia Scisciola,
Emanuele Barbato,
Francesco Prattichizzo,
Giuseppe Paolisso,
Simona Altieri,
Sanjay Rajagopalan,
Giovanni Falco,
Maria Luisa Balestrieri,
Antonio Ceriello,
Valeria Pellegrini,
Laura Graciotti,
Pasquale Paolisso,
Bruno D’Agostino,
Tatiana Spadoni,
Nunzia D’Onofrio,
Chiara Frigé,
Mario Siniscalchi,
Fabio Spinetti,
Gennaro Vigliotti,
Carmine Vecchione,
Albino Carrizzo,
Giulio Accarino,
Antonio Squillante,
Giuseppe Spaziano,
Davida Mirra,
Renata Esposito,
Silvana Canzano,
Ferdinando Carlo Sasso,
Franca Ferraraccio,
Iacopo Panarese,
Ciro Mauro,
A. Enrique Caballero
Summary
This landmark clinical study found that patients with micro- and nanoplastics detected in their carotid artery plaque had a significantly higher risk of heart attack, stroke, or death over a 34-month follow-up period compared to those without detectable plastics. This is one of the first studies to directly link microplastic presence in human blood vessels to worse cardiovascular outcomes. The findings suggest that plastic accumulation in arteries may be an important and previously unrecognized risk factor for heart disease.
In this study, patients with carotid artery plaque in which MNPs were detected had a higher risk of a composite of myocardial infarction, stroke, or death from any cause at 34 months of follow-up than those in whom MNPs were not detected. (Funded by Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale and others; ClinicalTrials.gov number, NCT05900947.).